Concepedia

Author

Cornelius J. Clancy

University of PittsburghORCID

Also Known As

C Clancy, C J Clancy, C. Clancy, C. J. Clancy, C.J. Clancy, Clancy, Cornelius J., Cornelius Clancy, Cornelius J Clancy, Cornelius J. Clancy, Cornelius Joseph Clancy

391

Publications

27K

Citations

76

H-Index

156

Concepts

All Affiliations

University of PittsburghVA Pittsburgh Healthcare SystemUniversity of Pittsburgh Medical CenterUniversity of FloridaFlorida College
CJ

About

Cornelius J. Clancy is an author at University of Pittsburgh specializing in medicine, clinical microbiology, and microbiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

45

76

4.8K

2

Health Sciences

25

28

2.3K

3

Public Health

6

6

442

4

Natural Sciences

5

5

168

5

Allergy

2

2

125

Cornelius J. Clancy

×

181

Publications

21.8K

Citations

67

H-Index

YearCitations

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America

Peter G. Pappas, Carol A. Kauffman, David R. Andes,

Clinical Infectious Diseases

2015

3.9K

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

J. Peter Donnelly, Sharon Chen, Carol A. Kauffman,

Clinical Infectious Diseases

2019

2.6K

Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2023

631

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> <sub>KPC-3</sub> Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Ryan K. Shields, Liang Chen, Shaoji Cheng,

Antimicrobial Agents and Chemotherapy

2016

476

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

Ryan K. Shields, M. Hong Nguyen, Liang Chen,

Antimicrobial Agents and Chemotherapy

2017

472

Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2022

458

Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion

Paul E. Verweij, Bart Rijnders, Roger J. M. Brüggemann,

Intensive Care Medicine

2020

426

T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial

Eleftherios Mylonakis, Cornelius J. Clancy, Luis Ostrosky‐Zeichner,

Clinical Infectious Diseases

2015

425

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

Ryan K. Shields, Brian A. Potoski, Ghady Haidar,

Clinical Infectious Diseases

2016

417

Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and <i>Pseudomonas aeruginosa</i> with Difficult-to-Treat Resistance (DTR-<i>P. aeruginosa</i>)

Pranita D. Tamma, Samuel L Aitken, Robert A. Bonomo,

Clinical Infectious Diseases

2020

405

Page 1